NEW YORK – BC Platforms said today that it has entered into a collaboration with Finnish company Blueprint Genetics to develop data-driven clinical genetic testing services for patients with rare diseases.
The partners will combine Blueprint Genetics' clinical genetic testing services with BC Platforms' data management technology to help hospital systems and life sciences companies incorporate large genetic datasets into patient care, research studies, and sponsored testing programs, they said.
Zurich, Switzerland-based BC Platforms, which also has R&D operations in Finland, and Blueprint Genetics will build a virtual center of excellence to support the integration of genetic testing and clinical data applications, they said. According to the companies, this platform will support efficient delivery of test results and related health information in hopes of improving patient care.
"We believe that together we can provide a highly competitive platform and a one-stop shop for genetic testing and data management to help patients suffering from rare inherited diseases," BC Platforms CEO Tero Silvola said in a statement.
"Linking our high-quality genetic testing with BC Platforms' data management capabilities allows us to improve patient outcomes, reduce operating costs in healthcare organizations, and speed up the time to discovery," added Blueprint Genetics CEO Tommi Lehtonen.
Two weeks ago, Blueprint Genetics announced that it would open a testing lab in North America to meet growing demand for its sequencing-based rare disease gene panels. The new lab will offer both NGS-based panels and biochemical tests, which Blueprint is bringing in house through a partnership with Austrian firm Archimedlife Medical Laboratory.